{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT00616109","nct_id":"NCT00616109","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct00616109. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Main interventional arm of study. Subjects who received maintenance sunitinib experimentally on this study were from a population of (consenting) patients with histologically or cytologically documented Extensive-State Small Cell Lung Cancer (ES-SCLC) who did not progress (were classified as Complete Response or \"CR\", Partial Response or \"PR\", or Stable Disease or \"SD\") after an induction chemotherapy (Cisplatin and etoposide)","label":"Maintenance Sunitinib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2011-01","type":"ACTUAL"},"conditions":["Extensive-Stage Small Cell Lung Cancer"],"enrollment":{"count":16,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"sunitinib","otherNames":["Sutent"],"type":"DRUG"}],"last_update":"2014-04-21","lead_sponsor":"University of Michigan Rogel Cancer Center","official_title":"Phase II Trial of Sunitinib (Sutent, SU11248) Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2009-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival Rate","timeFrame":"4 Months Post Treatment"}],"references":[{"citation":"Schneider BJ, Gadgeel SM, Ramnath N, Wozniak AJ, Dy GK, Daignault S, Kalemkerian GP. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer. J Thorac Oncol. 2011 Jun;6(6):1117-20. doi: 10.1097/JTO.0b013e31821529c3.","pmid":"21512407","type":"RESULT"}],"start_date":{"date":"2007-09"},"study_type":"INTERVENTIONAL","title":"Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC","url":"https://clinicaltrials.gov/study/NCT00616109"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct00616109"}